ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain

NCT ID: NCT00656305

Last Updated: 2020-02-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 147 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-03-31
• Study Completion Date: 2012-09-30

Brief Summary

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Conditions

Bone Metastases; Multiple Myeloma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

ExAblate Treatment Arm

Group Type: EXPERIMENTAL

ExAblate MRfFUS

Intervention Type: DEVICE

MR guided focused ultrasound.

ExAblate Sham Arm

Group Type: SHAM_COMPARATOR

ExAblate MRfFUS

Intervention Type: DEVICE

MR guided focused ultrasound.

Sham

Intervention Type: DEVICE

sham comparator

Interventions

ExAblate MRfFUS

MR guided focused ultrasound.

Intervention Type: DEVICE

Sham

sham comparator

Intervention Type: DEVICE

Other Intervention Names

MRgFUS; FUS; Focused Ultrasound; MR guided Focused Ultrasound

Eligibility Criteria

Inclusion Criteria

1. Men and women age 18 and older

2. Patients who are able and willing to give consent and able to attend all study visits

3. Patients who are suffering from symptoms of bone metastases or multiple myeloma bone lesions and are radiation failure patients:

Radiation failure candidates are those who have received radiation without adequate relief from metastatic bone pain as determined by the patient and treating physician, those for whom their treating physician would not prescribe radiation or additional radiation treatments, and those patients who refuse additional radiation therapy,

4. Patients who refuse other accepted available treatments such as surgery or narcotics for pain alleviation.

5. Patient with NRS (0-10 scale) pain score ≥ 4 irrespective of medication

6. Targeted tumor(s) are ExAblate device accessible and are located in ribs, extremities (excluding joints), pelvis, shoulders and in the posterior aspects of the following spinal vertebra: Lumbar vertebra (L3 - L5), Sacral vertebra (S1 - S5)

7. Targeted tumor (treated) size up to 55 cm2 in surface area

8. Patient whose targeted (treated) lesion is on bone and the interface between the bone and lesion is deeper than 10-mm from the skin.

9. Targeted (treated) tumor clearly visible by non-contrast MRI, and ExAblate MRgFUS device accessible

10. Able to communicate sensations during the ExAblate treatment

11. Patients on ongoing chemotherapy regimen for at least 1 month at the time of eligibility:

• with same chemotherapy regimen (as documented from patient medical dossier),

And

• Worst pain NRS still >= 4

And

• do NOT plan to initiate a new chemotherapy for pain palliation should be eligible for the study.

12. No radiation therapy to targeted (most painful) lesion in the past two weeks

13. Bisphosphonate intake should remain stable throughout the study duration.

14. Patients will have from 1 to 5 painful lesions and only the most painful lesion will be treated.

15. Patients with persistent distinguishable pain associated with 1 site to be treated (if patient has pain from additional sites, the pain from the additional sites must be evaluated as being less intense by at least 2 points on the NRS compared to the site to be treated).

Exclusion Criteria

1. Patients who either

• Need surgical stabilization of the affected bony structure (>7 fracture risk score, see Section 7.3) OR
• Targeted tumor is at an impending fracture site (>7 on fracture risk score, see Section 7.3).

OR

• Patients with surgical stabilization of tumor site with metallic hardware

2. More than 5 painful lesions, or more than 1 requiring immediate localized treatment

3. Targeted (treated) tumor is in the skull

4. Patients on dialysis

5. Patients with life expectancy < 3-Months

6. patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study.

7. Patients with unstable cardiac status including:

• Unstable angina pectoris on medication
• Patients with documented myocardial infarction within six months of protocol entry
• Congestive heart failure requiring medication (other than diuretic)
• Patients on anti-arrhythmic drugs

8. Severe hypertension (diastolic BP > 100 on medication)

9. Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations (weight >250 pounds), etc.

10. Patients with an active infection or severe hematological, neurological, or other uncontrolled disease.

11. Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist) including advanced kidney disease

12. KPS Score < 60 (See "Definitions" below)

13. Severe cerebrovascular disease (multiple CVA or CVA within 6 months)

14. Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately 2 hrs.)

15. Target (treated) tumor is less then 1cm from nerve bundles, bowels or bladder.

16. Are participating or have participated in another clinical trial in the last 30 days

17. Patients initiating a new chemotherapy regime, or radiation (for the targeted most painful lesion) within the last 2 weeks

18. Patients unable to communicate with the investigator and staff.

19. Patients with persistent undistinguishable pain (pain source unidentifiable)

20. Targeted (treated) tumor surface area >= 55 cm2

21. Patient whose bone-lesion interface is < 10-mm from the skin

22. Targeted (treated) tumor NOT visible by non-contrast MRI,

23. Targeted (most painful) tumor Not accessible to ExAblate

24. The targeted tumor is less than 2 points more painful compared to other painful lesions on the site specific NRS.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

InSightec

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University of California San Diego

La Jolla, California, United States

Stanford University Medical Center

Stanford, California, United States

University MRI & Diagnostic Imaging Centers

Boca Raton, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Weill Cornell Medical College

New York, New York, United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

University of Virginia Health System

Charlottesville, Virginia, United States

Toronto General Hospital

Toronto, Ontario, Canada

Rambam medical Center -The Pain palliation unit

Haifa, , Israel

Sheba Medical Center

Tel Litwinsky, , Israel

University of Rome "La Sapienza"

Rome, , Italy

Rostov State Research Institute of Oncology

Rostov-on-Don, , Russia

N. N. Petrov Institute of Oncology

Saint Petersburg, , Russia

Countries

United States; Canada; Israel; Italy; Russia

References

Bitton RR, Rosenberg J, LeBlang S, Napoli A, Meyer J, Butts Pauly K, Hurwitz M, Ghanouni P. MRI-Guided Focused Ultrasound of Osseous Metastases: Treatment Parameters Associated With Successful Pain Reduction. Invest Radiol. 2021 Mar 1;56(3):141-146. doi: 10.1097/RLI.0000000000000721.

Reference Type: DERIVED

PMID: 32858582 (View on PubMed)

Hurwitz MD, Ghanouni P, Kanaev SV, Iozeffi D, Gianfelice D, Fennessy FM, Kuten A, Meyer JE, LeBlang SD, Roberts A, Choi J, Larner JM, Napoli A, Turkevich VG, Inbar Y, Tempany CM, Pfeffer RM. Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results. J Natl Cancer Inst. 2014 Apr 23;106(5):dju082. doi: 10.1093/jnci/dju082.

Reference Type: DERIVED

PMID: 24760791 (View on PubMed)

Other Identifiers

BM004

Identifier Type: -

Identifier Source: org_study_id